CN114848681A - 一种免疫治疗组合物及其用途 - Google Patents
一种免疫治疗组合物及其用途 Download PDFInfo
- Publication number
- CN114848681A CN114848681A CN202210535346.6A CN202210535346A CN114848681A CN 114848681 A CN114848681 A CN 114848681A CN 202210535346 A CN202210535346 A CN 202210535346A CN 114848681 A CN114848681 A CN 114848681A
- Authority
- CN
- China
- Prior art keywords
- immunotherapeutic composition
- tumor
- osteosarcoma
- patients
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 60
- 238000009169 immunotherapy Methods 0.000 title description 17
- 230000001024 immunotherapeutic effect Effects 0.000 claims abstract description 40
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 22
- 239000002502 liposome Substances 0.000 claims abstract description 21
- 201000008968 osteosarcoma Diseases 0.000 claims abstract description 17
- 210000004698 lymphocyte Anatomy 0.000 claims abstract description 10
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 claims abstract description 8
- 206010027476 Metastases Diseases 0.000 claims abstract description 8
- 230000009401 metastasis Effects 0.000 claims abstract description 8
- 108700007621 mifamurtide Proteins 0.000 claims abstract description 8
- 229960005225 mifamurtide Drugs 0.000 claims abstract description 8
- JMUHBNWAORSSBD-WKYWBUFDSA-N mifamurtide Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)OCCNC(=O)[C@H](C)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O JMUHBNWAORSSBD-WKYWBUFDSA-N 0.000 claims abstract description 8
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 claims abstract description 8
- 230000003308 immunostimulating effect Effects 0.000 claims abstract description 7
- 210000004072 lung Anatomy 0.000 claims abstract description 7
- 201000001441 melanoma Diseases 0.000 claims abstract description 7
- 210000002540 macrophage Anatomy 0.000 claims abstract description 5
- 230000001394 metastastic effect Effects 0.000 claims abstract description 5
- 206010061289 metastatic neoplasm Diseases 0.000 claims abstract description 5
- 229960001438 immunostimulant agent Drugs 0.000 claims abstract description 4
- 239000003022 immunostimulating agent Substances 0.000 claims abstract description 4
- 230000000694 effects Effects 0.000 claims description 12
- 238000001356 surgical procedure Methods 0.000 claims description 11
- 210000001616 monocyte Anatomy 0.000 claims description 9
- 238000011282 treatment Methods 0.000 claims description 9
- 108700013048 CCL2 Proteins 0.000 claims description 8
- 102000000018 Chemokine CCL2 Human genes 0.000 claims description 8
- 230000000306 recurrent effect Effects 0.000 claims description 8
- 102000004127 Cytokines Human genes 0.000 claims description 7
- 108090000695 Cytokines Proteins 0.000 claims description 7
- 230000004083 survival effect Effects 0.000 claims description 7
- 238000002474 experimental method Methods 0.000 claims description 6
- 230000014509 gene expression Effects 0.000 claims description 6
- 238000009521 phase II clinical trial Methods 0.000 claims description 6
- 230000005909 tumor killing Effects 0.000 claims description 6
- 206010027458 Metastases to lung Diseases 0.000 claims description 5
- 230000004913 activation Effects 0.000 claims description 4
- 239000000427 antigen Substances 0.000 claims description 4
- 108091007433 antigens Proteins 0.000 claims description 4
- 102000036639 antigens Human genes 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 230000007246 mechanism Effects 0.000 claims description 4
- 230000000259 anti-tumor effect Effects 0.000 claims description 3
- 230000005875 antibody response Effects 0.000 claims description 3
- 238000001516 cell proliferation assay Methods 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 239000000839 emulsion Substances 0.000 claims description 3
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims description 3
- 229960001101 ifosfamide Drugs 0.000 claims description 3
- 230000001900 immune effect Effects 0.000 claims description 3
- 238000001802 infusion Methods 0.000 claims description 3
- 108020004999 messenger RNA Proteins 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 230000035755 proliferation Effects 0.000 claims description 3
- 230000028327 secretion Effects 0.000 claims description 3
- 229960005486 vaccine Drugs 0.000 claims description 3
- 230000005713 exacerbation Effects 0.000 claims description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
- 102000004125 Interleukin-1alpha Human genes 0.000 claims 1
- 108010082786 Interleukin-1alpha Proteins 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 201000011510 cancer Diseases 0.000 abstract description 6
- 230000005012 migration Effects 0.000 abstract description 6
- 238000013508 migration Methods 0.000 abstract description 6
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 abstract description 6
- 230000009215 host defense mechanism Effects 0.000 abstract description 3
- 230000002093 peripheral effect Effects 0.000 abstract description 3
- 230000008512 biological response Effects 0.000 abstract description 2
- 230000001105 regulatory effect Effects 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 description 14
- 102100034256 Mucin-1 Human genes 0.000 description 4
- 108010008707 Mucin-1 Proteins 0.000 description 4
- 210000001132 alveolar macrophage Anatomy 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
- 229930105110 Cyclosporin A Natural products 0.000 description 2
- 108010036949 Cyclosporine Proteins 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 description 2
- 229960001265 ciclosporin Drugs 0.000 description 2
- 229930182912 cyclosporin Natural products 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000000212 effect on lymphocytes Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000003024 peritoneal macrophage Anatomy 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 201000003076 Angiosarcoma Diseases 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001382 Experimental Melanoma Diseases 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011833 dog model Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000006353 environmental stress Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000001865 kupffer cell Anatomy 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 208000021039 metastatic melanoma Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000028550 monocyte chemotaxis Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dispersion Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
一种免疫治疗组合物及其用途，包括：亲脂性胞壁酰二肽(MDP)类似物‑微脂粒包裹的胞壁酰三肽磷脂酰乙醇胺，该免疫治疗组合物含有分支杆菌胞壁成分，为一种天然免疫刺激剂，其脂质体制剂易被组织(尤其是肺)中巨噬细胞摄取，而肺为骨肉瘤的常见转移部位。其具多种生物学反应调节活性，可刺激宿主防御机制，抑制肿瘤转移；可增强癌症病人体内外周淋巴细胞和肿瘤浸润淋巴细胞的运动迁移能，且可致黑色素瘤患者受损的肿瘤浸润淋巴细胞运动迁移能力恢复。
Description
技术领域
本发明涉及医学领域，尤其涉及一种免疫治疗组合物及其用途。
背景技术
癌症是世界范围内的第一大死亡起因，而且开发针对癌症的有效疗法仍然是研究和临床开发的最活跃领域之一。尽管已提出许多新办法来治疗和预防癌症，但许多癌症仍然具有较高的死亡率且可能难以治疗或对常规疗法相对不响应。
人的大多数癌症和血液学恶性的特征至少部分在于称为粘蛋白-1(MUC1)的蛋白质的异常过表达，该蛋白的正常功能是帮助保护上皮细胞免于毒素、微生物和其他类型的外部环境应激(Kufe等，MUC1是从两个亚基的非共价相互作用形成的异二聚体蛋白，所述两个亚基由单个转录本编码，然后翻译后加工成亚基，称为MUC1-N和MUC1-C。MUC1正常见于分泌性内皮细胞的顶端边界，且当细胞应答应激而失去极性时(正常细胞的一种可逆过程)，MUC1能与通常位于基底外侧边界的分子相互作用。另外，应答应激环境，MUC1-N亚基(一种含有用O-连接的多糖大量糖基化的可变数目串联重复(VNTR)的大蛋白)可脱落。
发明内容
针对现有技术中的上述不足，本发明提供了一种免疫治疗组合物及其用途，其具多种生物学反应调节活性，可刺激宿主防御机制，抑制肿瘤转移；可增强癌症病人体内外周淋巴细胞和肿瘤浸润淋巴细胞的运动迁移能，且可致黑色素瘤患者受损的肿瘤浸润淋巴细胞运动迁移能力恢复。
为了达到上述发明目的，本发明采用的具体方案为：
一种免疫治疗组合物及其用途，包括：亲脂性胞壁酰二肽(MDP)类似物-微脂粒包裹的胞壁酰三肽磷脂酰乙醇胺，该免疫治疗组合物含有分支杆菌胞壁成分，为一种天然免疫刺激剂，其脂质体制剂易被组织(尤其是肺)中巨噬细胞摄取，而肺为骨肉瘤的常见转移部位。
优选地，该免疫治疗组合物可致人单核细胞趋化和活化因子(MCAF)mRNA的表达呈快速而短暂的增加，但对淋巴细胞中MCAFmRNA水平无影响，表明MCAF可能参与了该免疫治疗组合物发挥肿瘤杀伤和免疫刺激活性的过程；该免疫治疗组合物可诱导单核细胞中细胞因子(IL-1α、-1β、-6和-8以及TNF-α)基因表达的增加，但对淋巴细胞无此作用，表明该免疫治疗组合物导致这些细胞因子的产生和分泌，可能是其发挥抗肿瘤作用的机制之一。
优选地，在45名无症状HIV阳性受试者中进行的一项小型试验显示，经3次给予Env2-3疫苗加mifamurtide乳剂的治疗，受试者因HIV包膜抗原所致淋巴细胞增殖反应和抗体反应均明显增强；在骨肉瘤患者中进行的一项试验显示，在手术切除肺转移灶后，持续给予该免疫治疗组合物脂质体治疗，可明显推迟肿瘤的复发。
优选地，在复发性骨肉瘤患者中进行的一项Ⅱ期临床试验显示，该免疫治疗组合物与异环磷酰胺联用治疗的耐受性良好，且不会导致因该免疫治疗组合物而引起的单核细胞活化减弱；在另一项Ⅱ期临床试验中，患复发性骨肉瘤且有肺转移而术后无病生存的28名受试病人使用2mg·m－2该免疫治疗组合物治疗，先每周2次，持续12周，再每周1次，持续12周，结果其肿瘤复发时间显著推迟，但最初的12周治疗无显著疗效。
优选地，又一项临床试验中，复发型骨肉瘤患者在术后24周里，每周2次接受2mg·m－2该免疫治疗组合物的1小时输注治疗，结果，其无恶化生存率较历史数据对照组明显提高。
优选地，还有一项小型临床试验显示，具有高复发风险的18名可切除黑色素瘤患者在术前1个月和术后5个月期间接受了该免疫治疗组合物治疗，结果虽然所有受试者的若干免疫学参数指标得以改善，但只有单核细胞的肿瘤杀伤活性和肿瘤增殖检测的临床表现最为突出。
本发明的有益效果为：
其具多种生物学反应调节活性，可刺激宿主防御机制，抑制肿瘤转移；可增强癌症病人体内外周淋巴细胞和肿瘤浸润淋巴细胞的运动迁移能，且可致黑色素瘤患者受损的肿瘤浸润淋巴细胞运动迁移能力恢复。
具体实施方式
以下通过具体实施例进一步描述本发明，但本发明不仅仅限于以下实施例。在本发明的范围内或者在不脱离本发明的内容、精神和范围内，对本发明进行的变更、组合或替换，对于本领域的技术人员来说是显而易见的，且包含在本发明的范围之内。
一种免疫治疗组合物及其用途，包括：亲脂性胞壁酰二肽(MDP)类似物-微脂粒包裹的胞壁酰三肽磷脂酰乙醇胺，该免疫治疗组合物含有分支杆菌胞壁成分，为一种天然免疫刺激剂，其脂质体制剂易被组织(尤其是肺)中巨噬细胞摄取，而肺为骨肉瘤的常见转移部位。
该免疫治疗组合物可致人单核细胞趋化和活化因子(MCAF)mRNA的表达呈快速而短暂的增加，但对淋巴细胞中MCAFmRNA水平无影响，表明MCAF可能参与了该免疫治疗组合物发挥肿瘤杀伤和免疫刺激活性的过程；该免疫治疗组合物可诱导单核细胞中细胞因子(IL-1α、-1β、-6和-8以及TNF-α)基因表达的增加，但对淋巴细胞无此作用，表明该免疫治疗组合物导致这些细胞因子的产生和分泌，可能是其发挥抗肿瘤作用的机制之一。在45名无症状HIV阳性受试者中进行的一项小型试验显示，经3次给予Env2-3疫苗加mifamurtide乳剂的治疗，受试者因HIV包膜抗原所致淋巴细胞增殖反应和抗体反应均明显增强；在骨肉瘤患者中进行的一项试验显示，在手术切除肺转移灶后，持续给予该免疫治疗组合物脂质体治疗，可明显推迟肿瘤的复发。在复发性骨肉瘤患者中进行的一项Ⅱ期临床试验显示，该免疫治疗组合物与异环磷酰胺联用治疗的耐受性良好，且不会导致因该免疫治疗组合物而引起的单核细胞活化减弱；在另一项Ⅱ期临床试验中，患复发性骨肉瘤且有肺转移而术后无病生存的28名受试病人使用2mg·m－2该免疫治疗组合物治疗，先每周2次，持续12周，再每周1次，持续12周，结果其肿瘤复发时间显著推迟，但最初的12周治疗无显著疗效。又一项临床试验中，复发型骨肉瘤患者在术后24周里，每周2次接受2mg·m－2该免疫治疗组合物的1小时输注治疗，结果，其无恶化生存率较历史数据对照组明显提高。还有一项小型临床试验显示，具有高复发风险的18名可切除黑色素瘤患者在术前1个月和术后5个月期间接受了该免疫治疗组合物治疗，结果虽然所有受试者的若干免疫学参数指标得以改善，但只有单核细胞的肿瘤杀伤活性和肿瘤增殖检测的临床表现最为突出。
实施例：一系列小鼠模型试验显示，全身性给予mifamurtide脂质体，可有效激活环孢素诱导免疫抑制小鼠的肺泡巨噬细胞，从而杀死肿瘤细胞，但并不阻断环孢素介导的对T淋巴细胞依赖性抗原SRBC的抗体产生的抑制作用；将该免疫治疗组合物溶于磷酸盐缓冲液中形成胶束后，以单剂量或多剂量经，给予小鼠，可诱导激活肺和腹膜巨噬细胞而杀灭肿瘤细胞，然而，经静脉或腹膜注射给予该免疫治疗组合物脂质体，则只能分别激活肺或腹膜巨噬细胞；对C57BL/6小鼠每周2次经，给予该免疫治疗组合物，可抑制同源B16黑色素瘤细胞的肺和淋巴结转移，但该免疫治疗组合物对已转移的黑色素瘤无作用；小鼠经单次亚致死剂量的辐射后，再接受该免疫治疗组合物脂质体治疗，可刺激血细胞生成，促进造血功能的恢复；对具免疫功能的肺炎杆菌性败血病小鼠单次给予预防性剂量的该免疫治疗组合物或其脂质体，可显著提高小鼠存活率，而多次给予预防性剂量的该免疫治疗组合物脂质体则效果更好；对白细胞缺乏症小鼠重复给予预防性剂量的该免疫治疗组合物脂质体，也可提高小鼠存活率，但并不能增加小鼠白细胞数量；对肾腺癌小鼠经给予该免疫治疗组合物脂质体，可极为有效地抑制肿瘤的特发性肺转移；预先给小鼠使用该免疫治疗组合物，再对其辐射，可使小鼠造血功能得以恢复，并使其免于死亡，而在辐射前，联合使用该免疫治疗组合物和吲哚美辛，则能加强这种保护作用；对BALB/c小鼠每日1次经给予该免疫治疗组合物卵磷脂脂质体，可持久性激活肺泡巨噬细胞，并预防肾细胞癌的实验性肺转移；接受过该免疫治疗组合物治疗的小鼠经辐射后，其骨髓和血液中核酸含量的恢复较未接受过治疗的小鼠明显更快。
大鼠结肠癌肝转移模型试验显示，该免疫治疗组合物脂质体可显著抑制肝中肿瘤的生长，其作用机制可能是促进具细胞毒性作用的巨噬细胞数量增加和间接通过肝巨噬细胞诱导细胞因子产生。犬模型试验显示，患特发性骨肉瘤和血管肉瘤的犬经手术后，再接受该免疫治疗组合物与化疗联用治疗；可有效安全地治疗转移灶；患口腔原发恶性黑色素瘤的犬经手术切除后，再接受该免疫治疗组合物治疗，可延缓肿瘤转移，显著提高存活率。
以上所述仅为本发明专利的较佳实施例而已，并不用以限制本发明专利，凡在本发明专利的精神和原则之内所作的任何修改、等同替换和改进等，均应包含在本发明专利的保护范围之内。
Claims (6)
1.一种免疫治疗组合物及其用途，其特征在于，包括：亲脂性胞壁酰二肽(MDP)类似物-微脂粒包裹的胞壁酰三肽磷脂酰乙醇胺，该免疫治疗组合物含有分支杆菌胞壁成分，为一种天然免疫刺激剂，其脂质体制剂易被组织(尤其是肺)中巨噬细胞摄取，而肺为骨肉瘤的常见转移部位。
2.根据权利要求1所述的一种免疫治疗组合物及其用途，其特征在于，该免疫治疗组合物可致人单核细胞趋化和活化因子(MCAF)mRNA的表达呈快速而短暂的增加，但对淋巴细胞中MCAFmRNA水平无影响，表明MCAF可能参与了本品发挥肿瘤杀伤和免疫刺激活性的过程；本品可诱导单核细胞中细胞因子(IL-1α、-1β、-6和-8以及TNF-α)基因表达的增加，但对淋巴细胞无此作用，表明本品导致这些细胞因子的产生和分泌，可能是其发挥抗肿瘤作用的机制之一。
3.根据权利要求1所述的一种免疫治疗组合物及其用途，其特征在于，在45名无症状HIV阳性受试者中进行的一项小型试验显示，经3次给予Env2-3疫苗加mifamurtide乳剂的治疗，受试者因HIV包膜抗原所致淋巴细胞增殖反应和抗体反应均明显增强；在骨肉瘤患者中进行的一项试验显示，在手术切除肺转移灶后，持续给予本品脂质体治疗，可明显推迟肿瘤的复发。
4.根据权利要求1所述的一种免疫治疗组合物及其用途，其特征在于，在复发性骨肉瘤患者中进行的一项Ⅱ期临床试验显示，该免疫治疗组合物与异环磷酰胺联用治疗的耐受性良好，且不会导致因本品而引起的单核细胞活化减弱；在另一项Ⅱ期临床试验中，患复发性骨肉瘤且有肺转移而术后无病生存的28名受试病人使用2mg·m－2本品治疗，先每周2次，持续12周，再每周1次，持续12周，结果其肿瘤复发时间显著推迟，但最初的12周治疗无显著疗效。
5.根据权利要求1所述的一种免疫治疗组合物及其用途，其特征在于，又一项临床试验中，复发型骨肉瘤患者在术后24周里，每周2次接受2mg·m－2该免疫治疗组合物的1小时输注治疗，结果，其无恶化生存率较历史数据对照组明显提高。
6.根据权利要求1所述的一种免疫治疗组合物及其用途，其特征在于，还有一项小型临床试验显示，具有高复发风险的18名可切除黑色素瘤患者在术前1个月和术后5个月期间接受了该免疫治疗组合物治疗，结果虽然所有受试者的若干免疫学参数指标得以改善，但只有单核细胞的肿瘤杀伤活性和肿瘤增殖检测的临床表现最为突出。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210535346.6A CN114848681A (zh) | 2022-05-17 | 2022-05-17 | 一种免疫治疗组合物及其用途 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210535346.6A CN114848681A (zh) | 2022-05-17 | 2022-05-17 | 一种免疫治疗组合物及其用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114848681A true CN114848681A (zh) | 2022-08-05 |
Family
ID=82637794
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210535346.6A Pending CN114848681A (zh) | 2022-05-17 | 2022-05-17 | 一种免疫治疗组合物及其用途 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114848681A (zh) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103408635A (zh) * | 2013-06-27 | 2013-11-27 | 深圳翰宇药业股份有限公司 | 一种合成米伐木肽的制备方法 |
| AU2014202478A1 (en) * | 2010-03-25 | 2014-05-29 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
-
2022
- 2022-05-17 CN CN202210535346.6A patent/CN114848681A/zh active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014202478A1 (en) * | 2010-03-25 | 2014-05-29 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| CN103408635A (zh) * | 2013-06-27 | 2013-11-27 | 深圳翰宇药业股份有限公司 | 一种合成米伐木肽的制备方法 |
Non-Patent Citations (1)
| Title |
|---|
| 佚名: "免疫治疗药Mifamurtide", 药学进展, vol. 33, no. 9, 25 September 2009 (2009-09-25), pages 430 - 431 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Keller et al. | Oncolytic viruses—immunotherapeutics on the rise | |
| RU2153332C2 (ru) | Способ сенсибилизации раковых клеток к лизису, опосредованному клетками-киллерами | |
| Goto et al. | Intradermal administration of lipopolysaccharide in treatment of human cancer | |
| Hodges et al. | CoQ_ {10}: could it have a role in cancer management? | |
| CN118105415A (zh) | 治疗剂、药盒、分离的重组溶瘤痘病毒在治疗肿瘤和/或癌症的药物中的用途 | |
| JP5889797B2 (ja) | ランゲルハンス細胞の免疫抑制を逆転させる方法 | |
| KR20230065977A (ko) | 암 치료를 위한 인터페론-기반 방법 및 약제학적 조합 | |
| WO2015027915A1 (zh) | 体内个体化系统免疫治疗方法和装置 | |
| KR20030041161A (ko) | 단핵구의 성숙을 촉진하는 방법 및 조성물 | |
| Pan et al. | Adenovirus mediated transfer of p53, GM-CSF and B7-1 suppresses growth and enhances immunogenicity of glioma cells | |
| WO1987006830A1 (en) | Lipopolysaccharide and natural factor compositions for anti-tumor therapy and method of treatment | |
| EP3697431A1 (en) | Treatment of neuropathy with dna construct expressing hgf isoforms with reduced interference from gabapentinoids | |
| CN114848681A (zh) | 一种免疫治疗组合物及其用途 | |
| Faries | Intralesional immunotherapy for metastatic melanoma: the oldest and newest treatment in oncology | |
| WO1988006452A1 (en) | Compositions for enhancing adcc therapy | |
| CN112569360A (zh) | 一种基于阻断pd-1/pd-l1的抗肿瘤药物组合物及其应用 | |
| Chun et al. | Combination immunotherapy of cancer in a mouse model: synergism between tumor necrosis factor and other defense systems | |
| Morecki et al. | Effect of indomethacin on tumorigenicity and immunity induction in a murine model of mammary carcinoma | |
| Yefenof et al. | Prophylactic intervention in radiation-leukemia-virus-induced murine lymphoma by the biological response modifier polysaccharide K | |
| WO2014139456A1 (zh) | 氢氧化铝在制备治疗肝癌药物中的应用 | |
| WO2018053270A1 (en) | Modified natural killer cells for the treatment of cancer | |
| CN113440601B (zh) | Nk细胞和tfpi联用在防治鼻咽癌中的应用 | |
| Jurin et al. | Porcine splenic peptides (Polyerga) decrease the number of experimental lung metastases in mice | |
| CN106540253A (zh) | cGAMP及其衍生物在制备抗肿瘤疫苗中的应用 | |
| Zarkovic et al. | Spleen Peptides (Polyerga™) Inhibit Development of Artificial Lung Metastases of Murine Mammary Carcinoma and Increase Efficiency of Chemotherapy in Mice |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |